A novel immune checkpoint siglec-15 antibody inhibits LUAD by modulating mφ polarization in TME

Background: Siglec-15 (S15) is a type-I transmembrane protein and is considered a new candidate of immune checkpoint inhibitor for cancer immunotherapy. Methods: In the present study, we first constructed and characterized a chimeric S15-specific monoclonal antibody (S15–4E6A). Then, the antitumor e...

Full description

Bibliographic Details
Main Authors: Xuejun Xiao, Yan Peng, Zheyue Wang, Louqian Zhang, Tingting Yang, Yangyang Sun, Yufeng Chen, Wenqing Zhang, Xinxia Chang, Wen Huang, Shuning Tian, Zhenqing Feng, Nabi Xinhua, Qi Tang, Yuan Mao
Format: Article
Language:English
Published: Elsevier 2022-07-01
Series:Pharmacological Research
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1043661822002146